More tools:Markets·Screener·Research·Chat

Pluri Inc. Common Stock (PLUR) Financial Statements

Pluri Inc. Common Stock
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001S8QJB7
XNAS · usd
1.28▲ 0.01 (0.79%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close1.27
Day's Range1.27 – 1.40
52-Week Range1.25 – 5.17
Volume17.5K
Avg Volume24.8K
Share Statistics
Shares Outstanding
Employees142
ExchangeXNAS
Listed1991-10-09
Share count as of May 13, 2026
Loading Income Statement…
Key questions about Pluri Inc. Common Stock (PLUR)
What is Pluri Inc. Common Stock's Market Cap?
Pluri Inc. Common Stock's Market Cap is $13.8M, based on as-reported figures from SEC (XBRL) filings.
What is Pluri Inc. Common Stock's Enterprise Value?
Pluri Inc. Common Stock's Enterprise Value is $10.8M, based on as-reported figures from SEC (XBRL) filings.
What is Pluri Inc. Common Stock's Price / Sales?
Pluri Inc. Common Stock's Price / Sales is 12.8×, based on as-reported figures from SEC (XBRL) filings.
What is Pluri Inc. Common Stock's EV / Revenue?
Pluri Inc. Common Stock's EV / Revenue is 10.0×, based on as-reported figures from SEC (XBRL) filings.
What is Pluri Inc. Common Stock's EV / EBITDA?
Pluri Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Pluri Inc. Common Stock's Revenue (TTM)?
Pluri Inc. Common Stock's Revenue (TTM) is $1.1M, based on as-reported figures from SEC (XBRL) filings.
What is Pluri Inc. Common Stock's Net Income (TTM)?
Pluri Inc. Common Stock's Net Income (TTM) is -$25.5M, based on as-reported figures from SEC (XBRL) filings.
What is Pluri Inc. Common Stock's EBITDA?
Pluri Inc. Common Stock's EBITDA is -$25.5M, based on as-reported figures from SEC (XBRL) filings.
What is Pluri Inc. Common Stock's Diluted EPS (TTM)?
Pluri Inc. Common Stock's Diluted EPS (TTM) is -2.37, based on as-reported figures from SEC (XBRL) filings.
What is Pluri Inc. Common Stock's EBITDA Margin?
Pluri Inc. Common Stock's EBITDA Margin is -2364.7%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
Revenues
YoY growth-60.9%+7.0%-3.1%+314.6%
Cost of revenues
Gross profit
% of revenue33.5%43.4%36.4%52.0%
Operating expenses:
Research and development expenses
Less: participation by the National Institute of Allergy and Infectious Diseases, or NIAID, the Israeli Innovation Authority, or IIA, and Horizon Europe
Research and development expenses, net
General and administrative expenses
Operating loss
% of revenue-3913.8%-3285.9%-2009.5%-1663.6%
Other financial income (expenses), net—
Interest expenses
Total financial income (expenses), net
Loss before taxes
Tax benefit—
Net loss
% of revenue-3695.8%-3470.7%-1940.5%-1952.0%
Net loss attributed to non-controlling interest
Net loss attributed to shareholders
% of revenue-3322.2%-3304.5%-1851.3%-1909.0%
Basic net loss per share (in Dollars per share)
Diluted net loss per share (in Dollars per share)